Doripenem

From Wikipedia, the free encyclopedia

Doripenem
Systematic (IUPAC) name
(4R,5S,6S)-6-(1-hydroxyethyl)-4-methyl-7-oxo-3- [(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl] sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
Identifiers
CAS number	148016-81-3
ATC code	J01DH04
PubChem	73303
Chemical data
Formula	C15H24N4O6S2
Mol. mass	420.50426 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	Renal
Half life	?
Excretion	?
Therapeutic considerations
Licence data	US
Pregnancy cat.	?
Legal status	℞-only(US)
Routes	IM, IV

Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.

Doripenem was approved by the United States Food and Drug Administration on October 12, 2007, to be sold under the tradename Doribax.^[1]

[edit] References

1. ^ U.S. Food and Drug Administration (October 17, 2007). "FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections". Press release. Retrieved on 2007-10-25.

v • d • e Antibacterials for systemic use: beta-lactam antibiotics - cephalosporins and related (J01D) First generation Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazedone, Cefazolin, Cefradine, Cefroxadine, Ceftezole Second generation Cefaclor, Cefamandole, Cefmetazole, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefuroxime Third generation Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpiramide, Cefpodoxime, Cefsulodin, Ceftazidime, Ceftibuten, Ceftizoxime, Ceftriaxone, Flomoxef, Latamoxef Fourth generation Cefepime, Cefozopran, Cefpirome, Cefquinome Fifth generation Ceftobiprole Other beta-lactam antibacterials Monobactams (Aztreonam), Carbapenems (Parenteral - Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Oral - Faropenem)